

Gabapentin and Methylcobalamin Tablets

GABIL™



Composition:

Each film-coated tablet contains
 Gabapentin USP 300 mg
 Methylcobalamin 500 mcg
 Excipients qs

Description:

Neuropathic pain of varied etiology is caused by a primary lesion or dysfunction in the nervous system, where pain is a primary manifestation. Studies have revealed that disorders of the myelin in both the CNS and the PNS is a feature in majority of the neuropathies. There is demyelination of the spinal cord, brain, optic and peripheral nerves leading to cell degeneration, loss of nerve function and finally damaged nerve fibers. Gabapentin prevents pain-related responses in neuropathic pain.

Methylcobalamin improves nerve function by contributing to neuromyelination, stimulate protein synthesis for neural regeneration and repair in peripheral neuropathies, regenerate neurons and myelin sheath that protect nerve axons and peripheral nerve thereby facilitating normal cell growth.

Gabapentin: Gabapentin is described as 1 (aminomethyl cyclohexanecarboxylic acid) with a molecular formula of C₂H₂NO₂ and a molecular weight of 171.24.
Methylcobalamin: Methylcobalamin is one of the two coenzyme forms of vitamin B12 (the other being adenosylcobalamin). It is a cofactor in the enzyme methionine synthase which functions to transfer methyl groups of the regeneration of methionine from homocysteine. Indication: For the treatment of neuropathic pain in adults.

Clinical Pharmacology:

Gabapentin: Gabapentin is structurally related to the neurotransmitter GABA (Gamma Amino Butyric Acid) but does not interact with GABA receptors, it is not metabolized to GABA or to GABA agonists, and is not an inhibitor of GABA uptake or degradation. The mechanism by which Gabapentin exerts its analgesic action is unknown, but in animal models of analgesia, Gabapentin prevents allodynia (Pain related behaviour in response to a normally innocuous stimulus) and hyperalgesia (exaggerated response to painful stimuli). In particular, Gabapentin prevents pain related responses in several animal models of neuropathic pain (eg. spinal nerve ligation models, streptozocin-induced diabetes models, spinal cord injury model, acute Herpes Zoster infection model). Gabapentin also decreases pain related responses after peripheral inflammation. Gabapentin bioavailability is not dose proportional, i.e. as dose is increased, bioavailability decreases. Food has only a slight effect on the rate and extent of absorption of Gabapentin. Less than 3% of Gabapentin circulates bound to plasma protein. Gabapentin is eliminated from the systemic circulation by renal excretion as unchanged drug. Half life is 5 to 7 hrs and is unaltered by dose or following multiple dosing. Gabapentin is not appreciably metabolized in humans nor does it interfere with the metabolism of commonly co administered antiepileptic drugs.

Gabapentin pharmacokinetics is not affected by repeated administration.

Elderly patients and patients with impaired renal function: Gabapentin plasma clearance is reduced. Dose adjustment is patients with compromised renal function or undergoing haemodialysis is recommended.

Haemodialysis: Haemodialysis has a significant effect on Gabapentin elimination in anuric subjects. Dose adjustment is patients undergoing haemodialysis is necessary. **Hepatic defects:** Since Gabapentin is not metabolized, no study is available on hepatic impairment.

Pediatric patients: The pharmacokinetic data reveals that the effective daily dose in paediatric patients with epilepsy aged 3 to 4 years should be 40mg/kg/day to achieve average plasma concentrations similar to those achieved in patients 5 years of age and older receiving Gabapentin at 30mg/kg/day.

Methylcobalamin:

Vitamin B12 is necessary for the formation of blood corpuscles, nerve sheaths and various proteins. It is also involved in fat and carbohydrate metabolism and is essential for growth.

Adenosylcobalamin is the co enzyme for isomerization of 1-Methylmalonyl Co enzyme A to Succinyl Coenzyme A (an important reaction in lipid and carbohydrate metabolism) and in Ribonucleotide reduction (which provides building blocks for DNA synthesis). Reactions involving methylcobalamin include biosynthesis of methionine, methane and acetate. There is evidence that Vitamin B12 is required the synthesis of folate polyglutamate (active coenzyme required in the formation of nerve tissue) and in the regeneration of folate during red blood cell formation.

Methylcobalamin is an endogenous Coenzyme B12 Methylcobalamin plays an important role in transmethylation as a coenzyme of methionine synthetase in the synthesis of methionine from homocystine.

Methylcobalamin is well transporter to nerve cells organelles, and promotes nucleic acid and protein synthesis in animal studies: Methylcobalamin was shown to be better transporter to nerve cell organelles than cyanocobalamin.

It has also been shown in experiments with cells from the brain origin and spinal nerve calls to be involved in the synthesis of thymidine from deoxyuridine, promotion of deposited folate utilization and metabolism of nucleic acid. Also, methylcobalamin plays role in nucleic acid and protein synthesis more than adenosylcobalamin does. Methylcobalamin promotes axonal transport and axonal regeneration: Methylcobalamin normalizes axonal skeletal protein transport in sciatic nerve cells from rat models with streptozocin-induced diabetes mellitus. It exhibits neuropathologically and electrophysiologically inhibitory effects on nerve degeneration in neuropathies induced by drugs, such as adriamycin, acrylamide, and vincristine, models of axonal degeneration in mice and neuropathies in rats with spontaneous diabetes mellitus. Methylcobalamin promotes myelination (phospholipids synthesis): Methylcobalamin promotes the synthesis of lecithin, the main constituent of medullary sheath lipids, and increases myelination of neurons in tissue culture more than adenosylcobalamin does.

Methylcobalamin resotes delayed synaptic transmission and diminished neurotransmitters to normal in animal studies: methylcobalamin restores end-plate potential induction early by addition, methylcobalamin normalizes diminished brain tissue levels of acetyl choline in rats fed a choline deficient diet.

Evidence indicates methylcobalamin is utilized more efficiently than cyanocobalamin to increase levels of one of the coenzyme forms of Vitamin B12

Experiments have demonstrated similar absorption of methylcobalamin following oral administration. The quantity of cobalamin detected following a small oral dose of methylcobalamin is similar to the amount following administration of cyanocobalamin, but significantly more cobalamin accumulates in liver tissue following administration of methylcobalamin. Human urinary excretion of methylcobalamin is about one third that of a similar dose of cyanocobalamin, indicating substantially greater tissue retention.

Contraindication:

Hypersensitivity to cobalamin products or cobalt or Gabapentin or any component of the preparation.
 Tobacco amblyopia. Should not be treated to treat megaloblastic anaemia of pregnancy. Should not be administered before pernicius anaemia or folate deficiency has been ruled out.

Precautions and Warnings:

Keep out of reach of children.

Gabapentin:

Gabapentin may cause dizziness, somnolence and other symptoms and signs of CNS depression. Accordingly, patients who are on the drug should be advised neither to drive a car nor to operate other complex machinery until they have gained sufficient experience on the drug to gauge the effects of the drug on their mental and/or motor performance adversely.

Patients who require concomitant treatment with morphine may experience increases in Gabapentin concentrations. Patients should be carefully observed for signs of CNS depression, such as somnolence, and the dose of Gabapentin or morphine should be reduced appropriately.

Drug withdrawal:

Antiepileptic drugs should not be abruptly discontinued because of the possibility of increasing seizure frequency in patients with epilepsy.

Tumorigenic Potential:

Clinical experience during Gabapentin's premarketing development provides no direct means to assess its potential for inducing tumors in humans. It is reported that in clinical studies in adjunctive therapy in epilepsy comprising 2085 patients-years of exposure in patients > 12 years of age, new tumors were reported in 10 patients (2 breast, 3 brain, 2 lungs, 1 adrenal, 1 non-Hodgkin's lymphoma, 1 endometrial carcinoma in situ), and preexisting tumors worsened in 11 patients (9 brain, 1 breast, 1 prostate) during or upto 2 years following discontinuation of Gabapentin.

Gabapentin and Methylcobalamin Tablets

GABIL™



Without knowledge of the background incidence and recurrence in a similar population not treated with Gabapentin, it is impossible to know whether the incidence seen in this cohort is or is not affected by treatment. Carcinogenesis, mutagenesis, impairment of fertility: The carcinogenic risk of Gabapentin in humans is unclear. Gabapentin was not found to have mutagenic or genotoxic potential and it also had no adverse effect on fertility or reproduction in animal studies. Pregnancy: This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Use in nursing mothers:

Gabapentin should be used in women who are nursing only if the benefits clearly outweigh the risks.

Pediatric use:

Safety and effectiveness of Gabapentin in the management of postherpetic neuralgia have not been established.

Methylcobalamin: The prolonged use of larger doses of methylcobalamin is not recommended for patients whose occupation requires the handling of mercury or mercury compounds.

Use cautiously in patients with hypertension, cardiovascular and lung diseases. Cardiac arrhythmias secondary to hypokalaemia during initial therapy have been reported. Vitamin B12 should be given prophylactically only when there is a reasonable indication. Administration of methylcobalamin doses greater than 10mcg daily, may produce a hematological response in patients with folate deficiency. It is important to monitor methylcobalamin concentrations in plasma and to obtain peripheral blood counts at intervals of 3 to 6 months to confirm that adequacy of therapy. Since refractoriness to therapy can develop at any time, evaluation must continue throughout the patient's life. Serum concentrations may be decreased by concurrent administration of oral contraceptives. Blood concentrations of methylcobalamin may be reduced if large doses of folate are taken continuously.

Drug Interactions:

Gabapentin: Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly co administered antiepileptic drugs.

Hydrocodone: Co administration of Gabapentin decreases hydro codone Cmax and AUC values in a dose-dependent manner relative to the administration of hydrocodone alone; hydrocodone increases Gabapentin AUC values by 14%.

Morphine: Patients who require concomitant treatment with morphine may experience increases in Gabapentin concentrations. Patients should be carefully observed for signs of CNS depression, such as somnolence, and the dose of Gabapentin or morphine should be reduced appropriately.

Cimetidine:

Cimetidine appeared to alter the renal excretion of both Gabapentin and creatinine, an endogenous marker of renal function. The effect of Gabapentin on cimetidine was not evaluated.

Oral contraceptive: The Cmax of northindrone was reported to be 13% higher when it was co administered with Gabapentin this interaction is not expected to be of clinical importance.

Antacid:

It is recommended that Gabapentin be taken at least two hours following administration of an antacid.

Effect of probenecid: Probenecid is a blocker of renal tubular secretion, Gabapentin pharmacokinetic parameters without and with probenecid were comparable. This indicates that Gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.

Methylcobalamin:

Tetracycline: Vitamin B12 should not be taken at the same time as the antibiotic Tetracycline because it interferes with the absorption and effectiveness of this medication. Vitamin B12 either alone or in combination with other B vitamins should be taken at different times of the day from tetracycline.

Chemotherapy Medications:

Blood levels of Vitamin B12 may be reduced when taking chemotherapy medications (particularly methotrexate) for cancer.

Absorption of cobalamin is impaired by alcohol, vitamin B6 (pyridoxine) deficiency, cholestyramine, para-aminosalicylic acid, colchicine, neomycin, the oral biguanides, metformin, histamine H2 receptor antagonists (cimetidine, ranitidine, etc.)

phenformin and possibly potassium chloride. A number of anticonvulsants-phenobarbitone, primidone, phenytoin, and ethylphenacemide can alter the metabolism of cobalamin in the cerebrospinal fluid and lead to neurophysiologic disturbances. Several substituted amide, lactone and lactum analogues of cyanocobalamin compete with binding sites on intrinsic factor and lead to depressed absorption of the vitamins. Nitrous oxide also interferes with cobalamin metabolism.

Adverse effects:

Gabapentin: The infrequently reported adverse events include confusion, depression, chest pain, cellulites, malaise, face edema, allergic reaction, abscess, chills and fever, hypertension, syncope, palpitation, migraine, phypotension, peripheral vascular disorder, abnormal stools, anorexia, diabetes mellitus, asthenia, infection, headache, abdominal pain, diarrhea, dry mouth, constipation, nausea, vomiting, flatulence, peripheral adema, weight gain, hyperglycemia, dizziness, somnolence, ataxia, abnormal thinking, abnormal gait, incoordination, amnesia, hypoesthesia, pharyngitis rash, amblyopia, conjunctivitis, diplopia, otitis media, ecchymose anaemia, hypoglycemia, weight loss, arthralgia, myalgia, leg cramps, vertigo, nervousness, neuropathy, anxiety rhinitis, pneumonia, pruritus, skin ulcer, dry skin, Herpes zoster, fungal dermatitis, urticaria, abnormal vision, taste perversion, deafness, urinary tract infection, dysuria, impotence, polyuria etc.

Methylcobalamin:

Generally well tolerated.

Overdose Management:

Gabapentin: Acute oral overdoses of Gabapentin upto 43 gms have been reported. In these cases double vision, slurred speech, drowsiness, lethargy, and diarrhea were observed. All patients recovered with supportive care, Gabapentin can be removed by haemodialysis.

Methylcobalamin:

No such case have been described in the literature and it is unlikely that any harm would result.

Dosage and Administration:

The drug should be given as directed by the physician. The general recommended therapy is to start as one tablet, single dose, on Day 1. Two tablets (Divided b.i.d) on Day 2, and three tablets (divided t.i.d) on Day 3. The dose may then be uptitrated up to 2 tablets, 3 times a day. The average effective dose of methylcobalamin has been found to be 1500 mcg/day which is achieved by giving atleast 3 tablets a day.

How supplied:

Strip of 10 tablets

Storage:

Store in a cool, dry place. Protect from light.

For further details, please contact:

Biocon Limited
20th KM, Hosur Road,
Electronics City,
Bangalore - 560 100, India

Manufactured by:

Swiss Garnier Life Sciences,
21 to 23, Industrial Area,
Mehatpur, Dist. UNA, Himachal Pradesh - 174 315

Marketed by:

Biocon Limited,
20th K.M. Hosur Road,
Electronics City, Bangalore - 560 100.
TM - Trade Mark of Biocon Limited

In case of any product related complaints or adverse effect related to Biocon products Call Toll Free No: 1800 102 9465

Or

Visit our website www.biocon.com and fill voluntary reporting form available under Report Adverse Events/ Side Effects and product complaints & send the duly filled form to us at the address mentioned in the web mail address.